Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

Catia Marzolini, Caroline Sabin, Franc¸ois Raffi, Marco Siccardi, Cristina Mussini, Odile Launay, David Burger, Bernardino Roca, Jan Fehr, Stefano Bonora, Amanda Mocroft, Niels Obel, Frederic Antoine Dauchy, Robert Zangerle, Charalambos Gogos, Nicola Gianotti, Adriana Ammassari, Carlo Torti, Jade Ghosn, Genevieve ChêneJesper Grarup, Manuel Battegay

Research output: Contribution to journalArticlepeer-review


Objective: The prevalence of overweight and obesity is increasing among HIV-infected patients. Whether standard antiretroviral drug dosage is adequate in heavy individuals remains unresolved.We assessed the virological and immunological responses to initial efavirenz (EFV)-containing regimens in heavy compared to normal-weight HIV-infected patients. Design: Observational European cohort collaboration study. Methods: Eligible patients were antiretroviral-naïve with documented weight prior to EFV start and follow-up viral loads after treatment initiation. Cox regression analyses evaluated the association between weight and time to first undetectable viral load (50 copies/ml) after initial suppression over 5 years of follow-up. Recovery of CD4+ cell count was evaluated 6 and 12 months after EFV initiation. Analyses were stratified by weight (kg) group (I - 55, 80, 85, 90, 95). Results: The study included 19 968 patients, of whom 9.1, 68.3, 9.1, 5.8, 3.5, and 4.3% were in weight groups I-VI, respectively. Overall, 81.1% patients attained virological suppression, of whom 34.1% subsequently experienced viral load rebound. After multiple adjustments, no statistical difference was observed in time to undetectable viral load and virological rebound for heavier individuals compared to their normal-weight counterparts. Although heaviest individuals had significantly higher CD4+ cell count at baseline, CD4+ cell recovery at 6 and 12 months after EFV initiation was comparable to normal-weight individuals. Conclusion: Virological and immunological responses to initial EFV-containing regimens were not impaired in heavy individuals, suggesting that the standard 600mg EFV dosage is appropriate across a wide weight range.

Original languageEnglish
Pages (from-to)193-200
Number of pages8
JournalAIDS (London, England)
Issue number2
Publication statusPublished - Jan 14 2015


  • Efavirenz
  • HIV
  • Immunological response
  • Virological response
  • Weight

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults'. Together they form a unique fingerprint.

Cite this